combinatorial immune checkpoint inhibitor targeting IL13RA2, CTLA4, and PD1

A recombinant, targeted multivalent combinatorial immune checkpoint inhibitor (ICI) designed for the treatment of glioblastoma (GBM). Developed as a heterodimeric construct, the molecule consists of two primary components: one targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA4) and the other targeting programmed cell death protein 1 (PD1). The construct is redirected specifically to GBM cells via interleukin-13 receptor subunit alpha-2 (IL13RA2), a tumor-restricted receptor overexpressed on the majority of GBM cells but absent in normal brain tissue. By combining dual checkpoint blockade with tumor-homing capability, this therapeutic candidate is designed to facilitate direct, localized interactions between T cells and GBM tumor cells within the immunosuppressive tumor microenvironment while minimizing systemic side effects.

Other names

combinatorial heterodimer simultaneously targeting PD1, CTLA4 and IL13RA2recombinant, targeted multivalent ICI